Dr Reddy's launch generic cancer drug in US market

Drug firm Dr Reddy's Laboratories said on Friday it has launched its generic Decitabine injection used in treatment of cancer in the American market after receiving approval from the US health regulator.

The company has launched the Decitabine for injection in the strength of 50 mg in the US market following approval by the United States Food & Drug Administration of Dr Reddy's abbreviated new drug applications, it said in a statement.

The company's product is generic version of Dacogen, manufactured and sold by Eisai Inc under license from Astex Pharmaceuticals Inc, it added.

"The Dacogen brand has US sales of approximately $260 million MAT (moving annual total) for the most recent twelve months ending in July 2013 according to IMS Health," Dr Reddy's said.

The company's Decitabine for injection 50 mg is available as a single dose vial, it added. Dacogen is used in treatment of myelodysplastic syndromes and for acute myeloid leukemia.